Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer--is it justified?

Clin Infect Dis. 1997 Aug;25(2):346-8. doi: 10.1086/516925.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents / pharmacology
  • Anti-Infective Agents / therapeutic use*
  • Bacterial Infections / epidemiology
  • Bacterial Infections / mortality
  • Bacterial Infections / prevention & control*
  • Ciprofloxacin / pharmacology
  • Ciprofloxacin / therapeutic use*
  • Drug Therapy / methods
  • Drug Therapy / psychology*
  • Enterobacter / drug effects
  • Escherichia coli / drug effects
  • Gram-Negative Bacterial Infections / drug therapy
  • Gram-Negative Bacterial Infections / prevention & control
  • Humans
  • Klebsiella / drug effects
  • Microbial Sensitivity Tests
  • Mortality
  • Neoplasms / complications*
  • Neutropenia / drug therapy*
  • Pseudomonas aeruginosa / drug effects
  • Staphylococcus / drug effects
  • Survival Analysis

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Ciprofloxacin